Literature DB >> 30626705

Breast tumour organoids: promising models for the genomic and functional characterisation of breast cancer.

Charlotte Roelofs1,2, Frédéric Hollande3, Richard Redvers1,2, Robin L Anderson1,2,3, Delphine Merino4,2,5,6.   

Abstract

Until recently, established cancer cell lines have been used extensively in breast cancer research, due largely to the difficulties associated with the manipulation and long-term maintenance in culture of primary tumour cells from patients. The recent development of organoid cultures has provided new opportunities to model and analyse patient samples, allowing the propagation of malignant cells under conditions that resemble the three-dimensional growth of breast tumours. They have proved efficacious in preserving the heterogeneity of primary samples and are emerging as a new model to further characterise the molecular features of breast cancer. Organoids formed from patient-derived cells are now in use for the evaluation of drug sensitivity and to validate disease-causing genomic variations. Here, the advantages and limitations of organoid cultures will be discussed and compared with the parallel development of other two- and three-dimensional culture strategies and with patient-derived xenografts. In particular, we will focus on the molecular characterisation of breast cancer organoids and provide some examples of how they have been used in functional studies.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  breast cancer; drug testing; genomics; organoids

Mesh:

Year:  2019        PMID: 30626705     DOI: 10.1042/BST20180375

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  8 in total

Review 1.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

2.  Sample preparation strategies for high-throughput mass spectrometry imaging of primary tumor organoids.

Authors:  Jillian Johnson; Joe T Sharick; Melissa C Skala; Lingjun Li
Journal:  J Mass Spectrom       Date:  2020-01-21       Impact factor: 1.982

Review 3.  [Application of Organoids in Lung Cancer Precision Medicine].

Authors:  Ziqi Jia; Naixin Liang; Shanqing Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-07-20

4.  Estrogen-related receptors are targetable ROS sensors.

Authors:  Mathieu Vernier; Catherine R Dufour; Shawn McGuirk; Charlotte Scholtes; Xiaojing Li; Guillaume Bourmeau; Hellen Kuasne; Morag Park; Julie St-Pierre; Etienne Audet-Walsh; Vincent Giguère
Journal:  Genes Dev       Date:  2020-02-20       Impact factor: 11.361

Review 5.  Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review.

Authors:  Sander Dumont; Ziga Jan; Ruben Heremans; Toon Van Gorp; Ignace Vergote; Dirk Timmerman
Journal:  J Ovarian Res       Date:  2019-11-08       Impact factor: 4.234

Review 6.  Advancement of Organoid Technology in Regenerative Medicine.

Authors:  Babak Arjmand; Zahra Rabbani; Faezeh Soveyzi; Akram Tayanloo-Beik; Mostafa Rezaei-Tavirani; Mahmood Biglar; Hossein Adibi; Bagher Larijani
Journal:  Regen Eng Transl Med       Date:  2022-08-08

7.  Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models.

Authors:  Alicja Urbaniak; Megan R Reed; Daniel Fil; Anika Moorjani; Sarah Heflin; Michał Antoszczak; Michał Sulik; Adam Huczyński; Michalina Kupsik; Robert L Eoff; Melanie C MacNicol; Timothy C Chambers; Angus M MacNicol
Journal:  Biomed Pharmacother       Date:  2021-06-12       Impact factor: 7.419

Review 8.  Reconstructing the tumor architecture into organoids.

Authors:  Zhimin Luo; Xingwu Zhou; Kalpana Mandal; Na He; Wally Wennerberg; Moyuan Qu; Xing Jiang; Wujin Sun; Ali Khademhosseini
Journal:  Adv Drug Deliv Rev       Date:  2021-06-19       Impact factor: 17.873

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.